The prevailing theory about the Omicron variant is that it is going to rip through the population quickly and possibly burn out, marking the downside of the COVID-19 pandemic. But researchers are expressing concern about a subvariant of Omicron dubbed BA.2 that appears to be tearing through Denmark, just as the first Omicron wave subsided.
Thermo Fisher Scientific launched a new collaborative unit that aims to standardize the metabolomics community’s efforts as the company engages in more large-scale cohort studies and clinical research.
California announced an app to help people track their exposure to the coronavirus, becoming the largest U.S. state to take advantage of new technology from smartphone software makers Apple Inc. and Alphabet Inc.’s Google.
With the opioid crisis gripping the United States, many doctors have been looking at alternate treatments to help patients with long-term chronic pain. A new study shows that the venom from a scorpion sting could provide a solution.
GlaxoSmithKline struck a research deal with the early pioneers of a prominent gene-editing technology at the University of California.
The U.S. Patent and Trademark Office granted Emmanuelle Charpentier — co-founder of ERS Genomics — the University of California, and the University of Vienna their first U.S. patent covering the use of CRISPR/Cas9 for gene editing.